Scanadu Inc., a Moffett Field, CA-based medtech company that is building a family of mobile medical products for consumers, raised $35m in Series B funding.
The round was led by Fosun International and Tencent Holdings Limited, with participation from China Broadband Capital and Iglobe Partners of Singapore, as well as A-round investors Relay Ventures, Redmile Group, Ame Cloud Ventures and Three Leaf Ventures, an affiliate of The Broe Group.
The company, which has raised $49.7m in total funding, intends to use the funds to continue to build out its family of products and obtain regulatory clearance in the U.S. and China.
Led by founder and CEO Walter De Brouwer, Scanadu is to complete shipment of their first set of investigational Scanadu Scout™ devices to their more than 8,000 Indiegogo supporters. The device measures for heart rate, core body temperature, blood oxygenation, and cuffless and calibration-free systolic and diastolic blood pressure in one scan in seconds, and shares those results to an app on Android and iOS smartphones.
The company is currently working toward FDA submission and approval for that device, as well as Scanadu Urine (formerly known as ScanaFlo), an at-home urine test that similarly shares important health data to the user’s smartphone.